Royce & Associates’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-106,700
| Closed | -$399K | – | 875 |
|
|
2023
Q3 | $399K | Hold |
106,700
| – | – | ﹤0.01% | 831 |
|
|
2023
Q2 | $456K | Hold |
106,700
| – | – | ﹤0.01% | 848 |
|
|
2023
Q1 | $730K | Hold |
106,700
| – | – | 0.01% | 807 |
|
|
2022
Q4 | $845K | Sell |
106,700
-2,577
| -2% | -$20.4K | 0.01% | 777 |
|
|
2022
Q3 | $1.05M | Sell |
109,277
-12,507
| -10% | -$120K | 0.01% | 729 |
|
|
2022
Q2 | $882K | Sell |
121,784
-21,163
| -15% | -$153K | 0.01% | 768 |
|
|
2022
Q1 | $1.85M | Buy |
142,947
+94,318
| +194% | +$1.22M | 0.02% | 723 |
|
|
2021
Q4 | $776K | Sell |
48,629
-98,394
| -67% | -$1.57M | 0.01% | 836 |
|
|
2021
Q3 | $2.36M | Buy |
147,023
+18,386
| +14% | +$296K | 0.02% | 720 |
|
|
2021
Q2 | $1.78M | Buy |
128,637
+1,164
| +0.9% | +$16.1K | 0.01% | 774 |
|
|
2021
Q1 | $1.86M | Sell |
127,473
-212,999
| -63% | -$3.11M | 0.01% | 763 |
|
|
2020
Q4 | $5.92M | Sell |
340,472
-30,042
| -8% | -$522K | 0.05% | 513 |
|
|
2020
Q3 | $6.8M | Buy |
370,514
+14,899
| +4% | +$273K | 0.07% | 398 |
|
|
2020
Q2 | $6.35M | Buy |
355,615
+57,103
| +19% | +$1.02M | 0.07% | 398 |
|
|
2020
Q1 | $4.84M | Buy |
+298,512
| New | +$4.84M | 0.07% | 386 |
|